Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease

N/AActive Not RecruitingNCT05101824

Gitte Fredberg Persson MD PhD67 enrolled

Overview

This is a prospective, investigator-initiated, phase II, multicentre-study, investigating the efficacy and toxicity of definitive SABR of osseous oligometastases, when pragmatically introduced into a daily clinical setting.

Patients with a histology or cytology proven non-hematological cancer and at least one lesion in the bones are eligible. Patients with de novo- and induced oligometastatic disease, as well as patients with oligo-recurrence or oligo-progression disease can be included. A total of 67 patients will be enrolled. The overall aim is to document long time follow-up in respect to local control rate, OS, PFS, rate of symptomatic skeletal event at the irradiated site(s), time to progression outside the radiation field at 1-, 2- and 5-years and acute/ late toxicities. The primary endpoint is the rate of local control 1-year post SABR. Patients will have a CT scan and a clinical evaluation every 3 month after SABR according to the standard clinical follow-up program. During the 1 year follow-up we also perform pain assessment (using the Numeric Pain Rating Scale), report the analgesic consumption and Quality of life (QoL) measured with EQ-5D-5L. Two dose levels are offered with either 37.5 gy in 3 fractions or 30 gy in 3 fractions, prescribed to the GTV.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Oligometastatic Disease Bone Metastases Stereotactic Body Radiotherapy

Interventions

SABRRADIATION

Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histology or cytology proven non-haematological cancer. * At least one lesion in the bones is required. * ECOG performance status ≤ 2. * ≥ 18 years old. * Life expectancy \> 6 months. * GTV diameter ≤ 5 cm. * In case of de novo OMD and OMD recurrence a maximum of 5 targets (including the primary tumour) in a maximum of 3 organ sites are allowed. * In case of OPD \* and induced OMD\*2 only 3 metastases (including the primary tumour) are allowed. * The metastatic lesion(s) must be visible on a CT- or MR- scan and suitable for treatment with SABR. * All metastatic sites are treated or planned for ablative therapy (including surgery) - for OPD only the sites in progression is required to fulfil this criterion. • A baseline scan within 28 days of inclusion (CT or PET- CT). * For spine/paraspinal targets, an MR scan is mandatory, if epidural growth cannot be precluded on the baseline CT scan. * No curative intended treatment option available. * An ablative strategy should be deemed clinically relevant and is at the discretion of the treating physician to decide. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patient cannot tolerate physical set up required for SABR. * Uncontrolled intercurrent illness. * Pregnancy. * Bilsky score ≥ 1b. If the patient is treated with surgery, a pre-operative Bilsky score ≥ 1b is an exclusion criterion as well. See appendix A for Bilsky score. * Presence of myelopathy from the target area. * Candidate for surgical treatment (determined by the institutions clinical oncologist, neurosurgeon or orthopaedic surgeon). * For spine/paraspinal lesions where epidural growth cannot be precluded on the baseline CT scan: patients for whom an MR scan is contraindicated. * Mechanical instability and/or fracture risk \*3. * For spine disease, involvement of ≥ three contiguous vertebrae. * Uncontrolled disease in respect to malignant pleural effusion, ascites, lymphangitic carcinomatosis, pleural carcinomatosis or peritoneal carcinomatosis. * Patients with uncontrolled brain metastases. * If the patient has received previous radiotherapy, the combined dose at the radiation site must not exceed the dose constraints according to Appendix B. -

Locations (6)

Aalborg Universitetshospital

Aalborg, Denmark

Rigshospitalet

Copenhagen, Denmark

Herlev Hospital

Herlev, Denmark

Odense University Hospital

Odense, Denmark

Outcomes

Primary Outcomes

local control rate (LC) at 1-year post SABR

Response evaluation is based on the interpretation of a experienced onco-radiologist and modifications from the MDACC response criteria's.

Time frame: 1-year post SABR

Secondary Outcomes

Rate of Symptomatic Skeletal Event (SSE) at the irradiated site(s)

Symptomatic Skeletal Event (SSE) of the irradiated site is defined as a radiographically verification of fracture (vertebral or non-vertebral, pathological or non-pathological), within or adjacent to the PTV of the irradiated site. The fracture must co-exist with one of the

Time frame: 3-, 6-, 12- and 24-months post SBRT

Pain, change from baseline evaluated by "Numeric Pain Rating Scale (NPRS)"

Response categories is based on patient reported pain scores (NPRS). The 11- 9 Protocol version 1.1, 01052020. Stereotactic ablative radiotherapy (SABR) of bony metastases in patients with oligometastatic disease - A phase II study point NPRS ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

Time frame: Measured at 2-, 12-, 24-, 36- and 52-weeks post SBRT

NCI CTCAE ≥ grade 3 toxicity

Cummulated fraction of patients, who encounter one or more ≥ grade 3 NCI CTCAE toxicity within the first 3-months after SBRT.

Time frame: Measured at 2-, 12-weeks post SBRT

NCI CTCAE ≥ grade 3 late toxicity

Cummulated fraction of patients, who encounter one or more ≥ grade 3 NCI CTCAE toxicity from 3-months and onward after SBRT including patients who have unresolved early toxicity (encontered within the first 3-months), that is not resolved at the 24-weeks follow-up.

Time frame: Measured at 3-, 6-, 12- and 24-months post SBRT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.